This trial is designed to study the effect of P-MNA (a dissolvable microneedle array) on healthy human volunteers, with the goal of determining how different factors affect the rate and extent of microneedle array dissolution. The trial will be conducted in two parts. In Part II, subjects will be randomized to one of four dose groups to receive either a placebo or a specified amount of doxorubicin in a tip-loaded, dissolvable microneedle array.
- Basal Cell Carcinoma
2 Primary · 0 Secondary · Reporting Duration: Up to 4 weeks after the last array application to a subject
5 Treatment Groups
Doxorubicin-containing MNA - 200 µg
1 of 5
Doxorubicin-containing MNA - 50 µg
1 of 5
Doxorubicin-containing MNA - 100 µg
1 of 5
Placebo MNA for Training
1 of 5
1 of 5
25 Total Participants · 5 Treatment Groups
Primary Treatment: Placebo MNA for Training · Has Placebo Group · Phase 1 & 2
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Age 18 - 75 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the scope of participants involved in this clinical research?
"Affirmative. As outlined on clinicaltrials.gov, this medical trial first opened for recruitment on September 24th 2021 and was last updated August 10th 2022 - actively seeking 25 participants from 2 distinct locations." - Anonymous Online Contributor
Is the age criterion for this experiment limited to individuals under 55 years of age?
"Those who apply for this trial must be between 18 to 75 years old. There are 95 studies available for minors and 325 research opportunities designated for seniors above the age of 65." - Anonymous Online Contributor
Is there an ongoing recruitment of participants for this clinical trial?
"Clinicaltrials.gov attests that this medical research is currently searching for participants, having been initially posted on September 24th 2021 and most recently amended on August 10th 2022." - Anonymous Online Contributor
What maladies have been demonstrated to be remedied by Placebo MNA for Training?
"Placebo MNA for Training is habitually utilized to treat lymphoma and Hodgkin's, as well as other diseases such as carcinoma, bronchogenic, neuroblastoma (NB), and Sezary Syndrome." - Anonymous Online Contributor
Does this research endeavor mark a novel application of methodology?
"Since 1997, Placebo MNA for Training has been the subject of clinical investigation. Alfacell's first trial concerning this medication took place that same year and involved 300 participants. After receiving Phase 3 approval, there are currently 360 trials underway in 66 different nations and 1941 cities worldwide." - Anonymous Online Contributor
Are there any prior studies which have utilized Placebo MNA for Training?
"The Placebo MNA for Training protocol was first implemented at Spectrum Health Hospital - Butterworth Campus in 1997. Since then, 677 trials have been completed and 360 are currently on-going with many based out of West Palm Beach, Florida." - Anonymous Online Contributor
Do I meet the qualifications necessary to participate in this medical experiment?
"This clinical trial is open to 25 men and women aged 18-75 with a diagnosis of basal cell carcinoma. In order to qualify, subjects must also fulfill the following criteria: general good health as assessed by the investigator, minimum granulocytes and platelets counts, serum creatinine below twice the upper limit of normal (ULN), AST, ALT, LDH and alkaline phosphatase all at or lower than three times ULN; no other clinically significant abnormal findings in medical history or physical examination; willingness to adhere to instructions from research team and sign informed consent form prior to study procedures; BCC confirmed histologically via" - Anonymous Online Contributor